KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Other Accumulated Expenses (2016 - 2025)

Travere Therapeutics' Other Accumulated Expenses history spans 12 years, with the latest figure at $3.2 million for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses fell 81.33% year-over-year to $3.2 million; the TTM value through Dec 2025 reached $3.2 million, down 81.33%, while the annual FY2025 figure was $3.2 million, 81.33% down from the prior year.
  • Other Accumulated Expenses reached $3.2 million in Q4 2025 per TVTX's latest filing, down from $5.4 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $17.1 million in Q4 2024 to a low of $3.2 million in Q4 2025.
  • Average Other Accumulated Expenses over 5 years is $7.5 million, with a median of $5.7 million recorded in 2022.
  • Peak YoY movement for Other Accumulated Expenses: surged 226.64% in 2024, then tumbled 81.33% in 2025.
  • A 5-year view of Other Accumulated Expenses shows it stood at $6.2 million in 2021, then decreased by 7.53% to $5.7 million in 2022, then fell by 8.48% to $5.2 million in 2023, then soared by 226.64% to $17.1 million in 2024, then crashed by 81.33% to $3.2 million in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Other Accumulated Expenses are $3.2 million (Q4 2025), $5.4 million (Q3 2025), and $14.3 million (Q2 2025).